NCT07818720尚未招募1 期
A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)
MycoMedica Life Sciences PBC0 个研究点目标入组 32 人开始时间: 2026年12月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 32
- 主要终点
- Number of participants with treatment-related adverse events as assessed by CTCAE v6.0
研究概览
简要总结
The goal of this clinical trial is to learn if MLS101 (psilocybin) is a possible treatment for women with Premenstrual Dysphoric Disorder (PMDD). The main question it aims to answer is:
• Test the safety and tolerability of the study drug, MLS101 in premenopausal women (ages 18-50 inclusive) with PMDD.
详细描述
The purpose of this trial is to investigate the safety and tolerability of intermittent low-dose MLS101 (psilocybin) 2mg, 4mg, and 8mg versus placebo in participants with PMDD. These doses are less than one third of the doses typically administered in high-dose psilocybin studies.
The study will enroll premenopausal women, ages 18-50 (inclusive) with an existing diagnosis of PMDD and history of having tried at least 1 prior treatment for PMDD. There is an initial Screening/Preparation Period of up to 2-5 weeks. The 16-day Treatment Period will span the luteal phase of 1 menstrual cycle. During this time, participants will receive 6 doses of MLS101 capsules in the clinic approximately every 3 days. After the Treatment Period, there is a Follow-up Period of approximately 1 month.
Participants will be monitored after receiving each dose for at least 8 hours in the clinic and must meet specified criteria before discharge. All participants will be escorted home by a companion or via concierge care service after each dosing session.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Provides informed consent for participating in the study
- •Biologically female participants 18-50 years of age (inclusive) at Screening and premenopausal
- •Body mass index (BMI) ≥ 18.5 and < 40.0 kg/m2
- •Menstrual cycle duration of 24-35 days (inclusive) reported at Screening
- •Menstrual cycles are sufficiently regular to allow estimation of menses onset with reasonable accuracy based on participant's reported history and the Investigator's assessment
- •Participant has an existing diagnosis of PMDD and history of at least one prior or current medically-supervised treatment for PMDD
- •CGI-S ≥ 4 for late luteal phase PMDD symptom severity and associated impairment at Screening
- •Mean VAS score ≥ 50 on any one of the 4 core symptoms of PMDD at Screening, as measured using the first 4 items on the PMTS-VAS
- •Participant is using a medically acceptable form of birth control for at least 8 weeks prior to receiving first dose of study drug and agrees to continue using medically acceptable birth control for at least 4 weeks post last dose in the study. Medically acceptable birth control methods include double-barrier methods used with spermicide, copper or low-dose levonorgestrel-releasing IUD, participant has had tubal ligation, participant is in a monogamous relationship with a vasectomized male or with another female, or participant is celibate as part of her lifestyle and will remain so throughout the study. (Note that for this study, oral, subdermal, transdermal, injectable, and vaginal ring hormonal contraceptives are not allowed).
- •If a participant is currently taking SSRI treatment, it must have been maintained as a stable monotherapy for at least 3 months prior to Screening with intent to continue unchanged for the duration of the study.
排除标准
- •Currently meets DSM-5 criteria for MDD, GAD, Panic Disorder, OCD, Anorexia, Bulimia, Binge Eating Disorder, Borderline Personality Disorder, or Anti-Social Personality Disorder, based on M.I.N.I.
- •History of meeting DSM-5 criteria for Major Depressive Episode within the past 6 months from Screening
- •History of meeting DSM-5 criteria for Panic Disorder, OCD, Anorexia, Bulimia, Binge Eating Disorder, Anti-Social Personality Disorder, or Borderline Personality Disorder within 24 months from Screening
- •History of meeting DSM-5 criteria for Substance or Alcohol Use Disorder in the last 2 years at Screening (Note: mild recreational cannabis use in the judgment of the Investigator, that does not meet criteria for moderate or severe Substance Use Disorder, is not exclusionary)
- •Lifetime history of any psychosis or mania not attributable to substance use
- •First degree relative with schizophrenia, schizoaffective disorder or bipolar I disorder
- •Confirmed to be in perimenopause, or diagnosis of Polycystic Ovary Syndrome based on ACOG/Rotterdam criteria, or diagnosis of symptomatic uterine fibroids
- •PMDD symptoms attributable to, or exacerbated by, hormonal contraceptives/treatments
- •Participant plans to start any new treatment for PMDD, or to stop any ongoing SSRI treatment during the study
- •Use of any herbal or supplement with known serotonin-enhancing properties (e.g. St. John's Wort, L-tryptophan, 5-hydroxytryptophan) within the past 3 months at Screening
- •Use of any hormonal contraceptive that works primarily by suppression of ovulation, for the past month at Screening. Therefore, use of oral, subdermal, transdermal, injectable, and vaginal ring hormonal contraceptives is excluded. (However, copper IUDs and hormonal IUDs that release low-dose levonorgestrel are acceptable.)
- •Use of any non-SSRI antidepressant, antipsychotic, or anticonvulsant within the past 3 months
- •Exposure to a neurosteroid, whether marketed or in a clinical trial, during the past 12 months
- •Requires ongoing pharmacologic treatment for Attention-deficit/hyperactivity disorder (ADHD)
- •Suicidal ideation with intent and plan, suicide attempt, or psychiatric hospitalization during the past 12 months, or an answer of "yes" to Question 4 or 5 on the Baseline/Screening version of the Columbia-Suicide Severity Rating Scale (C-SSRS)
- •Use of a classic (serotonergic) psychedelic in any form and at any dose in the past 6 months
- •Participation in another psychiatric clinical trial during the past 6 months, or a clinical trial of any other medical intervention during the past 3 months, at Screening
- •Estimated glomerular filtration rate (eGFR) below the limit of normal range (< 60 mL/min/1.73m2)
- •Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 x upper limit of normal (ULN)
- •Total bilirubin > 1.5 x ULN (unless the participant has predominantly unconjugated hyperbilirubinemia in the absence of other liver function test [LFT] abnormalities including elevated Direct [conjugated] Bilirubin)
- •History or presence of clinically significant cardiovascular disease including valvulopathies, cardiac valve abnormalities; or clinically significant heart murmurs, and/or screening echocardiogram, as determined by the Investigator
- •History of or presence of pulmonary hypertension
- •Abnormal and clinically significant ECG measurements at Screening (calculated as the average of 3 individual 12-lead ECG measurements) indicating a second- or third- degree atrioventricular block, or one or more of the following:
- •QRS ≥ 120 msec
- •QTcF > 470 msec
- •PR interval > 220 msec
- •Known personal or family history of congenital long QT syndrome or sudden death
- •Supine resting bradycardia (pulse < 45 bpm) or a supine resting tachycardia (pulse > 100 bpm) at Screening or Day 1
- •History of orthostatic hypotension or postural orthostatic tachycardic syndrome, multiple syncopes, or unresolved/ongoing clinically significant hypotensive episodes or symptoms of fainting, dizziness, or light-headedness
- •History or presence of a neurological or neurodegenerative disorder such Alzheimer's disease or Parkinson's disease, transient ischemic attack, stroke, seizure disorder, or behavioral disturbances resulting from other neurological disorders. (Note: occurrence of childhood febrile seizure is not exclusionary.)
- •Any evidence of current or previous clinically significant disease, e.g., clinically relevant hepatic impairment; clinically relevant renal impairment; diabetes mellitus, thyroid disorder (uncontrolled hypo- or hyperthyroidism), or other endocrine disease; cardiovascular disease (e.g., uncontrolled coronary artery disease, uncontrolled hypertension, uncontrolled hypercholesterolemia); uncontrolled gastrointestinal disease (e.g., active peptic ulcer; uncontrolled hematological disease; uncontrolled autoimmune disorders, or other which may impact or confound the results of the study according to the judgment of the Investigator or Sponsor Medical Monitor (MM)
- •Any medical condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas], or history of bariatric surgery). History of cholecystectomy ≥ 1 year prior to Screening would be allowable.
- •Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)
- •Donation or loss of 500 mL or more of plasma or whole blood within 30 days of Screening
- •Participant who, for any reason, is deemed by the Investigator to be inappropriate for this study; or has any chronic or acute medical condition which would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational product; or is unable to comply with the study protocol
研究组 & 干预措施
Placebo group will receive a total of 6 intermittent doses of placebo
Placebo Comparator
干预措施: Placebo capsules (Drug)
MLS101 2 mg group will receive a total of 6 intermittent doses at 2 mg/dose
Active Comparator
干预措施: MLS101 psilocybin (Drug)
MLS101 4 mg group will receive a total of 6 intermittent doses at 4 mg/dose
Active Comparator
干预措施: MLS101 psilocybin (Drug)
MLS101 8 mg group will receive a total of 6 intermittent doses at 8 mg/dose
Active Comparator
干预措施: MLS101 psilocybin (Drug)
结局指标
主要结局
Number of participants with treatment-related adverse events as assessed by CTCAE v6.0
时间窗: From baseline through the final telehealth visit at week 11
Safety and tolerability of MLS101 and placebo from baseline through Visit 11/Final Telehealth Visit (Day 44 ± 5) as assessed by type, frequency, severity, timing, and relationship to MLS101 of any adverse events (AEs), adverse events of special interest (AESIs) serious adverse events (SAEs)
次要结局
- No change from baseline to end of study in mitral valve leaflet thickness as measured by transthoracic echocardiogram(From baseline to week 11)
- Change in Maximum Plasma Concentreation (Cmax)(Day 1 of treatment only)
- Change in subjective psychedelic experience from pretreatment to 8 hours after treatment(From pretreatment to 8 hours after treatment each treatment day)
- Participant reported drug liking(Once at the end of treatment)
- No change from baseline in Standardized Field Sobriety Test (SFST)(From baseline pretreatment to 8 hours after treatment)
- Mini Mental Status Examination (MMSE) to assess general mental status(From pretreatment to 8 hours after treatment.)
- Change in suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C SSRS)(From pretreatment baseline to 8 hours after treatment and at each telehealth and clinic visits)
- Change in sleep quality from baseline to end of treatment(From baseline to day 17)
- Change in subjective psychedelic experience from pretreatment to 8 hours after treatment(Day 1 of treatment only, prior to treatment to 8 hours after treatment)
- Change in drug withdrawal symptoms from the day after the last treatment to the final telehealth visit(From the day after the last study treatment to the final telehealth visit)
研究者
相似试验
尚未招募
2 期
Psilocybin-Assisted TherapyNCT07332143Emory University150
进行中（未招募）
2 期
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic MalignanciesDepressionAnxietyNCT07336238University of Washington18
进行中（未招募）
1 期
Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSDPTSDNCT07275970Scottsdale Research Institute24
尚未招募
1 期
The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.NCT07433452Gabriella Gobbi50
尚未招募
2 期
MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') TrialAdvanced CancerDemoralizationExistential DistressPsychological DistressNCT07791901University of Calgary60